 <h1>Mepsevii Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>vestronidase alfa</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about vestronidase alfa. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Mepsevii.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to vestronidase alfa: intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Solution)</p><p>Anaphylaxis has occurred with vestronidase alfa-vjbk administration, as early as the first dose, therefore appropriate medical support should be readily available when vestronidase alfa-vjbk is administered. Closely observe patients during and for 60 minutes after vestronidase alfa-vjbk infusion. Immediately discontinue the vestronidase alfa-vjbk infusion if the patient experiences anaphylaxis.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, vestronidase alfa (the active ingredient contained in Mepsevii) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking vestronidase alfa:</p><p>
<i>Rare</i>
</p><ul>
<li>Bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>cough</li>
<li>difficulty swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>hives, itching, skin rash</li>
<li>pale skin, pain, or redness at the injection site</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>rapid weight gain</li>
<li>tightness in the chest</li>
<li>tingling of the hands or feet</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Fever with seizures</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of vestronidase alfa may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Rare</i>
</p><ul>
<li>Diarrhea</li>
<li>swelling at the injection site</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to vestronidase alfa: intravenous solution</i></p><h3>General</h3><p>The most frequently reported side effects were infusion site extravasation, diarrhea, rash, anaphylaxis, infusion site swelling, peripheral swelling, and pruritus.<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Anti-drug antibodies developed (78%), neutralizing antibodies developed (55.6%), anaphylaxis (16.67%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Febrile convulsion<sup>[Ref]</sup></p><p>A week 66 of treatment, 1 patient experiences a febrile convulsion during infusion of a 4 mg/kg dose.  The infusion was stopped and the patient was given anticonvulsants, antipyretics, and antibiotics and the adverse reaction resolved.  The patient was subsequently rechallenged without recurrence and continued on treatment with this drug.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (25%)</p>
<p><b>Common</b> (1% to 10%): Pruritus<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (25%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Peripheral swelling<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion site extravasation (33.3%)</p>
<p><b>Common</b> (1% to 10%): Infusion site swelling<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Mepsevii (vestronidase alfa)." Ultragenyx Pharmaceutical, Novato, CA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What is Mepsevii used to treat?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Mepsevii (vestronidase alfa)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: lysosomal enzymes</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Mepsevii &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Mucopolysaccharidosis Type VII</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to vestronidase alfa: intravenous solution</i></p><h3>General</h3><p>The most frequently reported side effects were infusion site extravasation, diarrhea, rash, anaphylaxis, infusion site swelling, peripheral swelling, and pruritus.<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Anti-drug antibodies developed (78%), neutralizing antibodies developed (55.6%), anaphylaxis (16.67%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Febrile convulsion<sup>[Ref]</sup></p><p>A week 66 of treatment, 1 patient experiences a febrile convulsion during infusion of a 4 mg/kg dose.  The infusion was stopped and the patient was given anticonvulsants, antipyretics, and antibiotics and the adverse reaction resolved.  The patient was subsequently rechallenged without recurrence and continued on treatment with this drug.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (25%)</p><p><b>Common</b> (1% to 10%): Pruritus<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (25%)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Peripheral swelling<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion site extravasation (33.3%)</p><p><b>Common</b> (1% to 10%): Infusion site swelling<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Mepsevii (vestronidase alfa)." Ultragenyx Pharmaceutical, Novato, CA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is Mepsevii used to treat?</li>
</ul><h2>More about Mepsevii (vestronidase alfa)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>Drug class: lysosomal enzymes</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Mepsevii &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Mucopolysaccharidosis Type VII</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>